[Featured Stock] Sinopex Rises on Success of Korea's First Artificial Kidney Dialysis Clinical Trial

Sinopex's stock price is showing strong performance in early trading. The news of successfully completing clinical trials for the blood filter (dialysis) used in artificial kidneys for the first time in Korea is believed to have driven the stock price up.

As of 9:10 AM on the 7th, Sinopex is trading at 5,410 KRW, up 11.32% (550 KRW) compared to the previous session.

Sinopex announced through a press release that the patient-use clinical trial conducted on 50 hemodialysis patients at five major hospitals in Korea was successfully completed last week. This is the first official clinical trial conducted with a domestically produced blood dialysis filter for artificial kidneys, marking 59 years since hemodialysis began in Korea.

Currently, blood filters for artificial kidneys are entirely imported under duty-free conditions, but Sinopex has succeeded in domestic production and obtained product approval from the Ministry of Food and Drug Safety in March last year.

This content was produced with the assistance of AI translation services.